|Over a week ago|
Senseonics files to sell 54.17M shares of common stock for holders 09:1202/1002/10/21
Unusually active option classes on open February 8th » 09:4002/0802/08/21
CHWY, UNG, CRSR, SENS, MARA, XOM, CSCO, NNDM
Unusual total active…
Unusual total active option classes on open include: Chewy (CHWY), U.S. Natural Gas Fund (UNG), Corsair Gaming (CRSR), Senseonics (SENS), Marathon Patent Group (MARA), Exxon Mobil (XOM), Cisco (CSCO), and Nano Dimension (NNDM).
Ascensia commences sales, marketing activities for Eversense XL CGM » 08:1202/0102/01/21
Senseonics announced that…
Senseonics announced that Ascensia Diabetes Care, or Ascensia, has commenced sales and marketing activities for the Eversense XL CGM system in key European markets, as part of their strategic partnership announced in August, 2020. Under terms of the commercial agreement, today Ascensia initiates distribution of the Eversense XL System in Germany, Italy, The Netherlands, Poland, Spain and Switzerland. In the U.S., Ascensia is already providing sales support for the original Eversense CGM system. Ascensia Diabetes Care is a global specialist diabetes care company that is dedicated to helping people living with diabetes.
|Over a month ago|
Fly Intel: Pre-market Movers » 08:5501/2201/22/21
ADMP, CFMS, RF, ALLY, FHN, SLB, HBAN, IBM, PPG, SENS, INTC
Check out this morning's…
Senseonics 51.9M share Spot Secondary priced at $1.925 » 06:1801/2201/22/21
The deal size was…
The deal size was increased to 51.9M shares from 26M shares. H.C. Wainwright acted as sole book running manager for the offering.
Senseonics Holder Masters reports 5.89% active stake » 17:4501/2101/21/21
Masters Capital reported…
Masters Capital reported its stake in the company in a 13D filing, which allows for activism. Masters stake is 26,754,201 shares of Common Stock or 5.89% of the shares of the Common Stock of Senseonics, based upon 454,056,000 shares of Common Stock outstanding as of January 11. According to Senseonics, the 26,754,201 shares of Common Stock include 24,754,198 shares of Series A Convertible Preferred Shares that may be converted for Common Shares of the Senseonics. Masters Capital specifically disclaim beneficial ownership in the shares of Common Stock reported herein except to the extent of their pecuniary interest therein.
Senseonics announces $50M bought deal offering of common stock » 17:1401/2101/21/21
Senseonics announced that…
Senseonics announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 25,974,026 shares of common stock of the company at a public offering price of $1.925 per share, less underwriting discounts and commissions. The company also has granted the underwriter a 30-day option to purchase up to an additional 3,896,103 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 26, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The gross proceeds of the offering are expected to be approximately $50M, prior to deducting underwriting discounts and commissions and estimated offering expenses and excluding the exercise of the underwriter's option to purchase additional shares. The company intends to use the net proceeds from this offering for general corporate purposes, including working capital, product development focused on working to complete the 365-day Eversense system, capital expenditures and supporting the collaboration with Ascensia Diabetes Care.
BTIG cuts Senseonics to Neutral, sees no fundamental reason for rapid rise » 16:5101/2001/20/21
BTIG analyst Marie…
BTIG analyst Marie Thibault downgraded Senseonics to Neutral from Buy. The analyst states that the stock has soared over 500% from its December 23rd level with no fundamental reason to explain the rise. Thibault adds that she continues to like the Eversense technology with a more favorable reimbursement landscape positioning the company to reach its projected sales targets, but she cannot justify a valuation multiple above the top-performing names in Diabetes Technology.
Senseonics downgraded to Neutral from Buy at BTIG » 16:3901/2001/20/21
BTIG analyst Marie…
BTIG analyst Marie Thibault downgraded Senseonics to Neutral from Buy.
Senseonics downgraded to Sell at Craig-Hallum » 08:1301/2001/20/21
As previously reported,…
As previously reported, Craig-Hallum analyst Alex Nowak downgraded Senseonics to Sell from Hold after a 500%-plus move in the stock. The company is now worth $800M on an FDA-approved product that did not gain material traction the first time and further unraveled amid COVID, the analyst contends. While he acknowledges that the company secured Ascensia as a WW sales partner for a second shot, Nowak argues that the combo is not worth the $800M priced by the market. He thinks a combo of an FDA approved product, established commercial partner, yet 2nd commercial attempt, high cash burn and still unproven CGM is worth about $200M.